Glenmark Pharmaceuticals shares rise over 2% on U.S. market launch of Vitamin K1 Injectable Emulsion

Glenmark Pharmaceuticals shares surged by over 2% today following the company’s announcement of the launch of Phytonadione Injectable Emulsion USP, 10 mg/mL Single Dose Ampules, in the U.S. market through its subsidiary, Glenmark Pharmaceuticals Inc., USA. This product introduction expands Glenmark’s institutional channel offerings, aligning with its strategic focus on quality and affordability.

Key Highlights of the Launch:

Advertisement

  • Product Details:
    • The Phytonadione Injectable Emulsion USP is bioequivalent to Hospira Inc.’s Vitamin K1 Injectable Emulsion USP, 10 mg/mL.
    • It is used to treat conditions related to Vitamin K deficiencies.
  • Market Data:
    • According to IQVIA, the Vitamin K1 Injectable Emulsion market recorded annual sales of approximately $19.7 million for the 12 months ending November 2024.
  • Management Commentary:
    • Marc Kikuchi, President & Business Head for North America, emphasized the company’s dedication to expanding its product portfolio to meet the evolving needs of the healthcare market.

About Glenmark:

Glenmark Pharmaceuticals is a global research-driven pharmaceutical company with a strong presence in branded, generics, and OTC segments. It operates in over 80 countries, supported by 11 advanced manufacturing facilities and a robust R&D pipeline, earning accolades for its contributions to healthcare and sustainability.